 |
23 Diseases |  |
162 Trials |
|
162 Trials |  |
4758 News |  |
| «12...4748495051525354555657...6061» |
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date, Combination therapy: Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. (clinicaltrials.gov) - Apr 11, 2018
P1/2, N=32, Recruiting, Sponsor: University of California, San Diego
Trial completion date: Nov 2018 --> Nov 2021 | Trial primary completion date: Nov 2017 --> Nov 2020
- | Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy. (Pubmed Central) - Apr 11, 2018
Trial completion date: Nov 2018 --> Nov 2021 | Trial primary completion date: Nov 2017 --> Nov 2020 No abstract available
- Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion date: CLL2-GiVe: Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL (clinicaltrials.gov) - Apr 10, 2018
P2, N=40, Recruiting, Sponsor: University of Ulm
No abstract available Trial completion date: Dec 2020 --> Mar 2022
- | MS-553 / MingSight Pharma
New P1 trial: A Study Of The Selective PKC-? Inhibitor MS- 553 (clinicaltrials.gov) - Apr 10, 2018
P1, N=47, Not yet recruiting, Sponsor: MingSight Pharmaceuticals, Inc.
- | Keytruda (pembrolizumab) / Merck (MSD), Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Enrollment open, PD(L)-1 Biomarker: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Apr 9, 2018
P2, N=37, Recruiting, Sponsor: University of Washington
Trial completion date: Dec 2020 --> Mar 2022 Not yet recruiting --> Recruiting
- || avadomide (CC-122) / BMS
Trial completion date, Trial primary completion date, Combination therapy: A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. (clinicaltrials.gov) - Apr 5, 2018
P1b, N=79, Recruiting, Sponsor: Celgene
Not yet recruiting --> Recruiting Trial completion date: Jan 2019 --> Sep 2019 | Trial primary completion date: Dec 2018 --> Apr 2019
- Tecentriq (atezolizumab) / Roche
Enrollment change, Trial withdrawal, Combination therapy: A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 5, 2018
P1, N=0, Withdrawn, Sponsor: Hoffmann-La Roche
Trial completion date: Jan 2019 --> Sep 2019 | Trial primary completion date: Dec 2018 --> Apr 2019 N=42 --> 0 | Recruiting --> Withdrawn
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: BO29562: A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov) - Mar 30, 2018
P1, N=38, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=42 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Mar 2021 | Trial primary completion date: Jan 2020 --> Mar 2021
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Phase classification: A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities (clinicaltrials.gov) - Mar 30, 2018
P, N=50, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Mar 2021 | Trial primary completion date: Jan 2020 --> Mar 2021 Phase classification: P=N/A --> P
- |||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open, Phase classification, Enrollment change: Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina (clinicaltrials.gov) - Mar 30, 2018
P, N=2, Enrolling by invitation, Sponsor: Hoffmann-La Roche
Phase classification: P=N/A --> P Not yet recruiting --> Enrolling by invitation | Phase classification: PN/A --> P | N=50 --> 2
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion date, Trial primary completion date, Combination therapy: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Mar 30, 2018
P1, N=60, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Enrolling by invitation | Phase classification: PN/A --> P | N=50 --> 2 Trial completion date: Mar 2019 --> Sep 2018 | Trial primary completion date: Mar 2019 --> Sep 2018
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion, Trial completion date, Trial primary completion date: ICLL-07: Phase II Trial GA101 Inbrutinib B CLL (clinicaltrials.gov) - Mar 30, 2018
P2, N=12, Completed, Sponsor: French Innovative Leukemia Organisation
Trial completion date: Mar 2019 --> Sep 2018 | Trial primary completion date: Mar 2019 --> Sep 2018 Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> Mar 2018 | Trial primary completion date: Dec 2017 --> May 2017
- |||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open, Phase classification: Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Mar 29, 2018
P, N=3300, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> Mar 2018 | Trial primary completion date: Dec 2017 --> May 2017 Not yet recruiting --> Recruiting | Phase classification: PN/A --> P
- | Enrollment open, Trial initiation date, FDG PET, Metastases: Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (clinicaltrials.gov) - Mar 29, 2018
P1, N=26, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting | Phase classification: PN/A --> P Not yet recruiting --> Recruiting | Initiation date: Oct 2018 --> Mar 2018
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) (clinicaltrials.gov) - Mar 27, 2018
P1/2, N=40, Active, not recruiting, Sponsor: University of California, San Diego
Not yet recruiting --> Recruiting | Initiation date: Oct 2018 --> Mar 2018 Recruiting --> Active, not recruiting | Trial completion date: May 2017 --> May 2019 | Trial primary completion date: May 2016 --> May 2018
- Enrollment closed, Enrollment change, Trial completion date, Combination therapy: A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Mar 26, 2018
P1, N=36, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial completion date: May 2017 --> May 2019 | Trial primary completion date: May 2016 --> May 2018 Recruiting --> Active, not recruiting | N=92 --> 36 | Trial completion date: Nov 2021 --> Jul 2021
- ||||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Trial completion, Combination therapy: A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) (clinicaltrials.gov) - Mar 22, 2018
P3, N=1418, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=92 --> 36 | Trial completion date: Nov 2021 --> Jul 2021 Active, not recruiting --> Completed
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed: NOBILITY: A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN) (clinicaltrials.gov) - Mar 21, 2018
P2, N=127, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Mar 21, 2018
P2, N=45, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial completion date: Mar 2022 --> Mar 2023
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion date: Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma (clinicaltrials.gov) - Mar 21, 2018
P2, N=64, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Mar 2022 --> Mar 2023 Trial completion date: Dec 2019 --> Dec 2020
- Ukoniq (umbralisib) / TG Therap
Trial completion date, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Mar 20, 2018
P1, N=30, Active, not recruiting, Sponsor: TG Therapeutics, Inc.
Trial completion date: Dec 2019 --> Dec 2020 Trial completion date: Dec 2017 --> Dec 2018
- Gazyva (obinutuzumab) / Roche, Biogen
Trial completion date, Trial primary completion date: A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation (clinicaltrials.gov) - Mar 20, 2018
P1, N=24, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2017 --> Dec 2018 Trial completion date: Aug 2018 --> Dec 2018 | Trial primary completion date: Aug 2018 --> Dec 2018
- | Trial completion date, Trial initiation date, Trial primary completion date, FDG PET, Metastases: Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (clinicaltrials.gov) - Mar 15, 2018
P1, N=26, Not yet recruiting, Sponsor: Mayo Clinic
Trial completion date: Aug 2018 --> Dec 2018 | Trial primary completion date: Aug 2018 --> Dec 2018 Trial completion date: May 2018 --> May 2019 | Initiation date: Mar 2018 --> Oct 2018 | Trial primary completion date: May 2018 --> May 2019
- ||| New P1 trial, Combination therapy: NP40126: A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL (clinicaltrials.gov) - Mar 15, 2018
P1b, N=172, Recruiting, Sponsor: Hoffmann-La Roche
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment change, Trial termination: Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Mar 14, 2018
P2, N=2, Terminated, Sponsor: University of Chicago
Trial completion date: May 2018 --> May 2019 | Initiation date: Mar 2018 --> Oct 2018 | Trial primary completion date: May 2018 --> May 2019 N=30 --> 2 | Completed --> Terminated; Trials was stopped early due to lack of funding.
- |||||||||| Imbruvica (ibrutinib) / AbbVie, J&J
New P3 trial: GLOW: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov) - Mar 11, 2018
P3, N=200, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Zelboraf (vemurafenib) / Roche
Trial initiation date: A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia (clinicaltrials.gov) - Mar 8, 2018
P2, N=28, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=30 --> 2 | Completed --> Terminated; Trials was stopped early due to lack of funding. Initiation date: Feb 2018 --> Feb 2018
- | Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, bendamustine / Generic mfg.
Journal: Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma. (Pubmed Central) - Mar 7, 2018
Initiation date: Feb 2018 --> Feb 2018 No abstract available
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment closed, Trial completion date, Trial primary completion date: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma (clinicaltrials.gov) - Mar 7, 2018
P1/2, N=317, Active, not recruiting, Sponsor: The Lymphoma Academic Research Organisation
No abstract available Trial primary completion date: Dec 2017 --> Jul 2018 | Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Mar 2022
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Biomarker, Trial completion date, Trial termination, Trial primary completion date: GAINED: GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Mar 7, 2018
P3, N=671, Terminated, Sponsor: The Lymphoma Academic Research Organisation
Trial primary completion date: Dec 2017 --> Jul 2018 | Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Mar 2022 Trial completion date: Feb 2019 --> Dec 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2019 --> Aug 2016; experimental treatment not Superior to standard - no need to continue the follow-up
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open: LYMA-101: Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance (clinicaltrials.gov) - Mar 7, 2018
P2, N=83, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Trial completion date: Feb 2019 --> Dec 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2019 --> Aug 2016; experimental treatment not Superior to standard - no need to continue the follow-up Not yet recruiting --> Recruiting
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
Enrollment open, Trial initiation date: LYSA: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas (clinicaltrials.gov) - Mar 7, 2018
P2, N=138, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Nov 2017 --> Feb 2018
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Trial initiation date: 17P.176: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Mar 6, 2018
P2, N=30, Recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Not yet recruiting --> Recruiting | Initiation date: Nov 2017 --> Feb 2018 Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Feb 2018
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Zelboraf (vemurafenib) / Roche
Trial initiation date: A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia (clinicaltrials.gov) - Mar 3, 2018
P2, N=28, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Dec 2018 --> Feb 2018 Initiation date: Jan 2018 --> Feb 2018
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Trial initiation date: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov) - Mar 3, 2018
P1b, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jan 2018 --> Feb 2018 Initiation date: Feb 2018 --> Feb 2018
- | Trial completion date, Combination therapy: A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Mar 3, 2018
P1, N=92, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Feb 2018 --> Feb 2018 Trial completion date: Jul 2021 --> Nov 2021
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion date, Trial primary completion date: NOBILITY: A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN) (clinicaltrials.gov) - Mar 3, 2018
P2, N=120, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jul 2021 --> Nov 2021 Trial completion date: Dec 2019 --> Dec 2019 | Trial primary completion date: Dec 2019 --> Dec 2019
- || Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion date: Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Mar 3, 2018
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2019 --> Dec 2019 | Trial primary completion date: Dec 2019 --> Dec 2019 Trial completion date: Mar 2023 --> Mar 2024
- Gazyva (obinutuzumab) / Roche, Biogen
Enrollment change, Trial initiation date, Trial withdrawal: Lenalidomide and Obinutuzumab for Previously Untreated CLL (clinicaltrials.gov) - Feb 23, 2018
P2, N=0, Withdrawn, Sponsor: University of California, San Diego
Trial completion date: Mar 2023 --> Mar 2024 N=25 --> 0 | Not yet recruiting --> Withdrawn | Initiation date: Dec 2017 --> Feb 2018
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Trial completion date, Trial primary completion date: Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. (clinicaltrials.gov) - Feb 22, 2018
P1, N=30, Recruiting, Sponsor: Michael Choi
N=25 --> 0 | Not yet recruiting --> Withdrawn | Initiation date: Dec 2017 --> Feb 2018 Trial primary completion date: Nov 2017 --> Nov 2019 | Trial completion date: Nov 2018 --> Nov 2020
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Trial initiation date: 17P.176: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas (clinicaltrials.gov) - Feb 20, 2018
P2, N=30, Not yet recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Trial primary completion date: Nov 2017 --> Nov 2019 | Trial completion date: Nov 2018 --> Nov 2020 Initiation date: Nov 2017 --> Dec 2018
- | New P1 trial, FDG PET, Metastases: Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (clinicaltrials.gov) - Feb 13, 2018
P1, N=26, Not yet recruiting, Sponsor: Mayo Clinic
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Zelboraf (vemurafenib) / Roche
Enrollment open: A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia (clinicaltrials.gov) - Feb 12, 2018
P2, N=28, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Initiation date: Nov 2017 --> Dec 2018 Not yet recruiting --> Recruiting
- | Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov) - Feb 9, 2018
P1b, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: GIOTTO: Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients (clinicaltrials.gov) - Feb 8, 2018
P2, N=29, Terminated, Sponsor: Fondazione Italiana Linfomi ONLUS
However, the enrolled patients concluded therapy and continued into the follow-up phase. The study was closed only after LVLP.
- ||| Calquence (acalabrutinib) / AstraZeneca
Enrollment open, Combination therapy: ACE-CL-003: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL (clinicaltrials.gov) - Feb 7, 2018
P1b, N=72, Recruiting, Sponsor: Acerta Pharma BV
The study was closed only after LVLP. Active, not recruiting --> Recruiting
- Tecentriq (atezolizumab) / Roche
Enrollment open, Combination therapy: A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Feb 5, 2018
P1, N=42, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Trial primary completion date, Combination therapy: Phase 1b Safety and Efficacy Study of TRU-016 (clinicaltrials.gov) - Jan 26, 2018
P1b, N=123, Recruiting, Sponsor: Aptevo Therapeutics
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2018 --> Jun 2019
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Zelboraf (vemurafenib) / Roche
New P2 trial: A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia (clinicaltrials.gov) - Jan 24, 2018
P2, N=28, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Tecentriq (atezolizumab) / Roche
Enrollment open, Combination therapy: BO29562: A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov) - Jan 24, 2018
P1, N=46, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2018 --> Jun 2019 Suspended --> Recruiting